Arcutis Biotherapeutics
ARQT
Market cap $1.11B

9.49 USD

-0.23

2.37%

At close Oct 17, 4:00 PM EDT

After hours

9.49

+0.00

0.00%

1 day

-2.37%

5 days

-2.57%

1 month

-8.49%

3 months

-7.59%

6 months

-7.41%

Year to date

176.68%

1 year

146.49%

5 years

-56.47%

About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Employees: 296

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

158% more call options, than puts

Call options by funds: $7.03M | Put options by funds: $2.73M

68% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 28

12% more funds holding

Funds holding: 164 [Q1] → 183 (+19) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 55

2.75% less ownership

Funds ownership: 112.03% [Q1] → 109.28% (-2.75%) [Q2]

8% less capital invested

Capital invested by funds: $1.28B [Q1] → $1.18B (-$99.7M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

58%

upside

Avg. target

$17

79%

upside

High target

$18

90%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Jefferies Kambiz Yazdi 100% 1-year accuracy 1 / 1 met price target	58%upside $15	Buy Initiated	28 Aug 2024
Needham Serge Belanger 49% 1-year accuracy 43 / 88 met price target	90%upside $18	Buy Reiterated	15 Aug 2024
Needham Serge Belanger 49% 1-year accuracy 43 / 88 met price target	90%upside $18	Buy Reiterated	30 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ARQT published over the past 30 days

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 95,000 restricted stock units of Arcutis' common stock as well as options to purchase an aggregate of 38,000 shares of Arcutis' common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe and well tolerated across all subgroups Data presented at the 2024 European Academy of Dermatology & Venereology Congress WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology and immunology, today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials showing that ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of AD in individuals regardless of race, ethnicity, and Fitzpatrick skin types.

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp Supplemental New Drug Application (sNDA) supported by positive efficacy and safety data from Phase 2b and pivotal Phase 3 trials, and long-term ZORYVE cream plaque psoriasis program WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 37,000 restricted stock units of Arcutis' common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 3, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Arcutis Biotherapeutics, Inc. is a biotech company based in California that markets two dermatological products, ZORYVE cream and foam, containing roflumilast, a PDE4 inhibitor. Despite initial struggles post-IPO, Arcutis has seen a significant increase in revenues and a narrowing of losses in Q2 2024, with new product approvals and collaborations. Analysts predict strong growth potential for ZORYVE, but competition in the dermatological market poses a challenge for Arcutis to maintain and grow market share.

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Latha Vairavan - VP, Finance and Head of IR Frank Watanabe - President & CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Securities Serge Belanger - Needham Chris Shibutani - Goldman Sachs Operator Hello, and thank you for standing by. Welcome to Arcutis Biotherapeutics Q2 2024 Earnings Call.

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), please note that in the section of Recent Corporate Highlights, in the third bullet point, the date for the extended maturity should be August 2029, not June 2029.

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Zacks Investment Research

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $1.16 per share a year ago.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs.

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

See News Rankings

Charts implemented using Lightweight Charts™